Drug that hinders blood vessel growth under study in ovarian cancer

March 09, 2005

A drug that may help prevent recurrence of ovarian cancer by inhibiting development of new blood vessels essential to cancer growth is under study at the Medical College of Georgia.

MCG is among some 25 centers nationally enrolling patients in remission to see if the investigational drug A6 can help them stay that way, says Dr. Sharad Ghamande, MCG gynecologic oncologist and a principal investigator on the study.

In the new study, participants will give themselves daily subcutaneous injections of the drug for four weeks, followed by seven days off. The cycle can be repeated up to 11 times if the disease remains in remission and there are no significant medication side effects.

"For a tumor to grow and spread, it needs blood supply," says Dr. Ghamande. "This blood supply arises de novo. The cancer produces cytokines (growth factors) that stimulate growth of vessel buds around it in a process called angiogenesis. This particular medication targets receptors on new budding blood vessels in an attempt to down-regulate them and prevent growth. If that process is shut down, the tumor should not grow or spread."

A6 has been shown to inhibit cancer metastasis in animal studies and showed "encouraging responses" in patients with advanced ovarian cancer in Phase 1 clinical trials, according to Virgil Thompson, president and chief executive officer of Angstrom Pharmaceuticals, Inc. Daily injections of A6 also were well-tolerated by patients in the earlier study, according to the San Diego-based company.

About 24,000 new cases of ovarian cancer are diagnosed each year and about three-quarters of those new patients have advanced disease. "Ovarian cancer has no early signs and symptoms and there is not yet a screening test, such as the Pap smear for cervical cancer," Dr. Ghamande says.

Despite the advanced stage of their disease at diagnosis, many women go into clinical remission following surgery and chemotherapy. Afterward, they are followed with regular physical exams and monitoring of CA 125 levels. CA 125 is a tumor marker expressed in about 90 percent of ovarian cancer cells in patients with advanced disease. MCG is participating in a separate trial of a monoclonal antibody that targets CA 125 as a different approach to forestalling cancer recurrence.

Despite initial success, ovarian cancer often recurs within two years, with increasing CA 125 levels typically as the first sign. Five-year survival rates are about 30 percent to 35 percent for stage three disease and 5 percent to 10 percent for the more-advanced stage four.

Patients in remission today may opt for an additional year of chemotherapy, which may delay recurrence but does not always translate to a longer life, Dr. Ghamande says. Also, the side effects of chemotherapy often mean well-intended patients never complete that second year.

A6 may one day offer another option for these women. The current study explores the safety and efficacy of two different doses of the drug compared to placebo. Study participants must be in clinical remission and have a history of normal CA 125 levels that have begun to rise but still have no evidence of cancer on physical exam or computerized tomography scan. Approximately 60 patients will be enrolled nationally; MCG hopes to enroll about five.
-end-
Dr. Michael S. Macfee, chief of the MCG Section of Gynecologic Oncology, is a co-investigator on the study. For more information, call study coordinator Nora McClendon at 706-721-5557.

Medical College of Georgia at Augusta University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.